Aduro Biotech Stock News

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aduro BioTech (ADRO – Research Report) today and set a

Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL)

If successful, the IPO would be the second of the month on the U.S. exchange by a Canadian cancer drug developer, following Friday’s debut by Montreal’s Repare Therapeutics

"Nessuno deve essere lasciato da solo". Lo dichiara Daria Pulz, consigliera regionale di Adu, illustrando gli emendamenti presentati al disegno di legge si variazione al bilancio. (ANSA)

State law directs California cities to approve accessory dwelling unit permits that satisfy certain conditions.

Aduro BioTech Inc (NASDAQ:ADRO) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 2,920,000 shares, an increase of 6.6% from the May 31st total of 2,7

An interior designer, remodeler and real estate agent predict post-pandemic home improvements.

Montreal cancer drug developer hits $1-billion valuation; oversubscribed offering is a big win for Quebec investors that backed the domestic biotech company

Repare said in a release late Thursday it would sell 11 million shares at US$20 apiece

PHILADELPHIA, PA / ACCESSWIRE / June 18, 2020 / Kaskela Law LLC announces that it is investigating Aduro Biotech, Inc. ("Aduro Biotech") (NASDAQ:ADRO) on behalf of the company's shareholders. ...

The company, which will now offer 10 million shares at US$18 to US$20 each, said its underwriters have the option to buy another 1.5 million shares at that price

Repare said in a filing it will offer 7.4 million shares at US$16 to US$18 each. Its underwriters have the option to buy another 1.1 million shares

CREME DE LA CREPE FRENCH RESTAURANT OPEN NOW FOR DINE IN 310...

William Blair analyst Matt Phipps maintained a Hold rating on Aduro BioTech (ADRO – Research Report) on June 9. The

Although Fusion is part of a trend, it is exceptional in another respect: It is one of the only Canadian biotech companies that has attracted a Canadian institutional investor from outside of Quebec